La jolla Pharmaceutical
La Jolla Pharmaceutical is a biopharmaceutical company that develops and markets five critical care and infectious disease therapeutics targeting drug-resistant infections and life-threatening conditions. The company operates as a subsidiary of Innoviva Specialty Therapeutics following acquisition by Innoviva, Inc. (NASDAQ: INVA).
- Company typePrivate
- Founded1989
- HeadquartersSan Diego, United States
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What La jolla Pharmaceutical does
La Jolla Pharmaceutical is a biopharmaceutical company that develops and commercializes innovative therapeutics for critical care and infectious diseases, with particular focus on conditions involving drug-resistant microorganisms. The company markets a portfolio of five pharmaceutical products: GIAPREZA (angiotensin II) for vasodilatory shock; XACDURO (sulbactam/durlobactam) and ZEVTERA (ceftobiprole medocaril) as injectable critical care therapies; and NUZOLVENCE (zoliflodacin) and XERAVA (eravacycline) as treatments for drug-resistant infections. These assets were developed through substantial clinical investment, supported by approximately $190.9M in cumulative equity funding raised between 2011 and 2015, and supplemented by the 2020 acquisition of Tetraphase Pharmaceuticals which added eravacycline to the portfolio.
The company was acquired by Innoviva, Inc. (NASDAQ: INVA), a diversified healthcare holding company that reinvests royalty streams from GlaxoSmithKline respiratory drugs (Trelegy Ellipta and Breo Ellipta) into specialty therapeutics acquisitions. Following the acquisition, La Jolla Pharmaceutical's products are now marketed through Innoviva Specialty Therapeutics, a subsidiary of Innoviva. The company is headquartered in San Diego, California, employs between 51-100 people, and distributes its products globally through healthcare providers, hospitals, and specialty pharmacies. Leadership includes CFO Michael Hearne and Director Laura L. Douglass. Standalone revenue figures are not publicly disclosed as La Jolla Pharmaceutical's results are consolidated within Innoviva's broader financials.
La jolla Pharmaceutical firmographics
Firmographics- Name
- La jolla Pharmaceutical
- Website
- https://lajollapharmaceutical.com
- Company type
- Private
- Founded year
- 1989
- Operating status
- Acquired
- Headcount range
- 51–100 employees
- Short description
- La Jolla Pharmaceutical is a biopharmaceutical company that develops and markets five critical care and infectious disease therapeutics targeting drug-resistant infections and life-threatening conditions. The company operates as a subsidiary of Innoviva Specialty Therapeutics following acquisition by Innoviva, Inc. (NASDAQ: INVA).
- Ownership category
- akta.pro rank
La jolla Pharmaceutical industry classification
Industry- Product category
- Specialty Pharmaceuticals
- SIC
- Services-Misc Health & Allied Services, Nec (8090)
- akta.pro primary industry
- Specialty Care Pharmaceuticals (HLAIAAAB)
Keywords
Where La jolla Pharmaceutical is headquartered
LocationHeadquarters
- HQ city
- San Diego
- HQ country
- United States
- HQ region
- North America
Markets served
La jolla Pharmaceutical business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Operations, Marketing or Sales, Personnel
Distribution channels1 record
Marketing channels1 record
La jolla Pharmaceutical product offering
Product offeringCore offering
La Jolla Pharmaceutical is a biopharmaceutical company that develops and markets innovative pharmaceutical therapies for patients in critical care and infectious disease. The company offers a portfolio of five marketed products including GIAPREZA (angiotensin II) for vasodilatory shock, XACDURO (sulbactam/durlobactam) and ZEVTERA (ceftobiprole) as injectable critical care therapies, and NUZOLVENCE (zoliflodacin) and XERAVA (eravacycline) for drug-resistant infections.
Product overview
Innoviva Specialty Therapeutics operates as a biotechnology company developing and delivering innovative therapies for patients in critical care and infectious disease. The company offers a portfolio of five marketed pharmaceutical products: GIAPREZA (angiotensin II) for critical care, XACDURO (sulbactam/durlobactam) and ZEVTERA (ceftobiprole) as injectable critical care therapies, and NUZOLVENCE (zoliflodacin) and XERAVA (eravacycline) for infectious diseases caused by drug-resistant microorganisms. These therapies represent both new treatments and established standards for critical care and infectious disease care.
Differentiator
Problem solved
Functional benefit
Products and services
- GIAPREZA (angiotensin II)
Companies that use La jolla Pharmaceutical
Customer profileSegments2 records
Ideal customer profiles1 record
La jolla Pharmaceutical technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
La jolla Pharmaceutical partnerships and signals
Strategic signalScale indicators2 records
Recent moves5 records
Expansion highlights4 records
La jolla Pharmaceutical competitors and assessment
Company assessmentBroad incumbents
- Merck & Co. Major pharmaceutical company with established antibiotics and critical-care products. Competes with La Jolla's hospital portfolio while operating across a much wider therapeutic range.
- Pfizer: Large-cap pharmaceutical company with a significant anti-infectives portfolio and hospital-channel sales infrastructure. Competes with La Jolla on broad-spectrum antibiotics and offers overlapping products in pneumonia and SSSI.
- Shionogi & Co. Global Japanese pharmaceutical company with a major anti-infectives franchise and a partner role on ceftobiprole. Overlaps with La Jolla in critical-care antibiotics but operates across many broader therapeutic areas.
Direct peers
- Paratek Pharmaceuticals: Specialty antibiotic company with hospital-channel commercial infrastructure focused on serious community-acquired infections. Highly comparable to La Jolla in therapeutic focus (anti-infectives) and customer base (hospital ID teams).
- Tetraphase Pharmaceuticals: Antibiotics developer of eravacycline (XERAVA), acquired by La Jolla in 2020. Direct historical peer and now integrated into the La Jolla product line.
- Nabriva Therapeutics: Specialty biopharma developing and commercializing antibiotics for serious infections, including community-acquired bacterial pneumonia. Closely comparable in scale, therapeutic area, and critical-care focus.
- Basilea Pharmaceutica: Swiss anti-infectives specialist and originator of ceftobiprole (ZEVTERA) and other hospital antibiotics. Direct strategic peer given the ZEVTERA relationship and shared anti-infective R&D focus.
- Iterum Therapeutics: Clinical and early-commercial-stage anti-infective company focused on resistant pathogens, including oral sulopenem. Comparable in therapeutic focus (drug-resistant infections) and similar size to La Jolla.
- Melinta Therapeutics: Hospital-focused antibiotics company marketing several FDA-approved anti-infectives (e.g., Baxdela, Vabomere) targeting resistant pathogens. Direct overlap with La Jolla's XACDURO, NUZOLVENCE, and ZEVTERA in indication and channel.
- Entasis Therapeutics: Anti-infective company also acquired by Innoviva, focused on drug-resistant infections including Xacduro-adjacent indications. Highly comparable as a sibling entity under the same parent holding company.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks6 records
Key highlights5 records
Customer concentration
La jolla Pharmaceutical social profiles
Digital presenceLa jolla Pharmaceutical financial estimates
Financial estimateRevenue estimate
Valuation estimate
La jolla Pharmaceutical leadership team
Management profileNumber of profiles
Profiles2 records
La jolla Pharmaceutical funding detail
Funding detailFunding overview
Funding rounds4 records
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
La jolla Pharmaceutical M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about La jolla Pharmaceutical
What does La jolla Pharmaceutical do?
La Jolla Pharmaceutical is a biopharmaceutical company that develops and markets innovative pharmaceutical therapies for patients in critical care and infectious disease. The company offers a portfolio of five marketed products including GIAPREZA (angiotensin II) for vasodilatory shock, XACDURO (sulbactam/durlobactam) and ZEVTERA (ceftobiprole) as injectable critical care therapies, and NUZOLVENCE (zoliflodacin) and XERAVA (eravacycline) for drug-resistant infections.
Is La jolla Pharmaceutical a public or private company?
La jolla Pharmaceutical is a private company. It is classified as corporate owned and is currently acquired.
When was La jolla Pharmaceutical founded?
La jolla Pharmaceutical was founded in 1989. It employs 51 to 100 people.
Where is La jolla Pharmaceutical based?
La jolla Pharmaceutical is headquartered in San Diego, United States, in the North America region.
Who are La jolla Pharmaceutical's main competitors?
Broad incumbents on record are Merck & Co., Pfizer and Shionogi & Co.. Direct peers are Paratek Pharmaceuticals, Tetraphase Pharmaceuticals, Nabriva Therapeutics, Basilea Pharmaceutica, Iterum Therapeutics, Melinta Therapeutics and Entasis Therapeutics.
Does La jolla Pharmaceutical have an API?
No public API is recorded for La jolla Pharmaceutical.
What industry is La jolla Pharmaceutical in?
La jolla Pharmaceutical's product category is Specialty Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAB, Specialty Care Pharmaceuticals. Its SIC code is 8090.